Vanda Pharmaceuticals (NASDAQ:VNDA) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Rating) in a research report released on Thursday. The brokerage issued a strong-buy rating on the biopharmaceutical company’s stock.

Vanda Pharmaceuticals Price Performance

NASDAQ:VNDA opened at $6.52 on Thursday. The business’s 50-day moving average is $7.08 and its two-hundred day moving average is $8.76. Vanda Pharmaceuticals has a 12 month low of $6.05 and a 12 month high of $12.34. The firm has a market capitalization of $370.21 million, a PE ratio of 54.34 and a beta of 0.72.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, SVP Timothy Williams sold 8,437 shares of the firm’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $6.24, for a total value of $52,646.88. Following the transaction, the senior vice president now directly owns 111,814 shares of the company’s stock, valued at $697,719.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Mihael Hristos Polymeropoulos sold 22,426 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $6.23, for a total transaction of $139,713.98. Following the sale, the chief executive officer now directly owns 1,499,440 shares of the company’s stock, valued at $9,341,511.20. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Timothy Williams sold 8,437 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $6.24, for a total value of $52,646.88. Following the sale, the senior vice president now directly owns 111,814 shares in the company, valued at $697,719.36. The disclosure for this sale can be found here. Insiders have sold 46,549 shares of company stock valued at $290,324 over the last three months. 7.00% of the stock is owned by company insiders.

Institutional Trading of Vanda Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its stake in Vanda Pharmaceuticals by 1.2% in the third quarter. BlackRock Inc. now owns 9,796,633 shares of the biopharmaceutical company’s stock worth $96,790,000 after purchasing an additional 114,055 shares in the last quarter. State Street Corp grew its stake in Vanda Pharmaceuticals by 22.1% in the first quarter. State Street Corp now owns 4,063,298 shares of the biopharmaceutical company’s stock worth $45,956,000 after purchasing an additional 735,865 shares in the last quarter. Vanguard Group Inc. grew its stake in Vanda Pharmaceuticals by 1.5% in the third quarter. Vanguard Group Inc. now owns 3,894,554 shares of the biopharmaceutical company’s stock worth $38,478,000 after purchasing an additional 56,822 shares in the last quarter. Renaissance Technologies LLC grew its stake in Vanda Pharmaceuticals by 13.3% in the second quarter. Renaissance Technologies LLC now owns 3,636,433 shares of the biopharmaceutical company’s stock worth $39,637,000 after purchasing an additional 427,819 shares in the last quarter. Finally, Macquarie Group Ltd. grew its stake in Vanda Pharmaceuticals by 1.8% in the third quarter. Macquarie Group Ltd. now owns 2,928,542 shares of the biopharmaceutical company’s stock worth $28,944,000 after purchasing an additional 50,962 shares in the last quarter. 97.22% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

(Get Rating)

Vanda Pharmaceuticals, Inc engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.